Dr Reddy's acquires GSK penicillin assets in US
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories is establishing a bridgehead into the US antibiotics market through the acquisition of GlaxoSmithKline's penicillin manufacturing site in Bristol, Tennessee, and US rights for the Augmentin and Amoxil brands. GSK will retain the existing rights for these brands outside the US.